10.26
5.42%
-0.58
Neumora Therapeutics Inc stock is traded at $10.26, with a volume of 496.36K.
It is down -5.42% in the last 24 hours and down -37.83% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
See More
Previous Close:
$10.84
Open:
$10.84
24h Volume:
496.36K
Relative Volume:
0.51
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-5.9714
EPS:
-1.7182
Net Cash Flow:
$-198.33M
1W Performance:
-24.84%
1M Performance:
-37.83%
6M Performance:
+6.02%
1Y Performance:
-14.78%
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
NMRA | 10.26 | 1.74B | 0 | -274.18M | -198.33M | -1.7182 |
VRTX | 467.43 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.66 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 565.62 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.53 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.40 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-12-23 | Initiated | Deutsche Bank | Hold |
Oct-10-23 | Initiated | BofA Securities | Buy |
Oct-10-23 | Initiated | Guggenheim | Buy |
Oct-10-23 | Initiated | JP Morgan | Overweight |
Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
Oct-10-23 | Initiated | Stifel | Buy |
Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 EPS Estimate for Neumora Therapeutics Cut by Analyst - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat
Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register
Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World
Objective long/short (NMRA) Report - Stock Traders Daily
Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN
What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownHere's Why - MarketBeat
Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCognex (NASDAQ:CGNX) - Benzinga
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Neutral - MarketBeat
JPMorgan downgrades Neumora stock, warns of potential downside without data clarity - Investing.com UK
Critical Analysis: Neumora Therapeutics (NMRA) and The Competition - Defense World
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
(NMRA) On The My Stocks Page - Stock Traders Daily
Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5%Time to Sell? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling - Defense World
SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Bleakley Financial Group LLC Sells 1,966 Shares of Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by SG Americas Securities LLC - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock - MarketBeat
Neumora Therapeutics director Matthew Fust sells $370,961 in stock - Investing.com India
Neumora Therapeutics director Matthew Fust sells $370,961 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLC - MarketBeat
(NMRA) Investment Analysis - Stock Traders Daily
This trade activity should not be overlooked: Neumora Therapeutics Inc. (NMRA) - SETE News
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider Selling - Defense World
Have you been able to find a good deal on Neumora Therapeutics Inc.’s shares? - US Post News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics executive sells over $200k in company stock - Investing.com India
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Fust Matthew K | Director |
Oct 17 '24 |
Option Exercise |
6.81 |
7,739 |
52,730 |
27,839 |
Fust Matthew K | Director |
Oct 18 '24 |
Sale |
17.03 |
14,049 |
239,319 |
20,100 |
Fust Matthew K | Director |
Oct 17 '24 |
Sale |
17.01 |
7,739 |
131,643 |
20,100 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):